ABBV-105|BTK Inhitibor&Antagonist&Agonist|DC Chemicals

Cas No.:
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

ABBV-105 (ABBV105) is a potent, selective, irreversible, covalent inhibitor of BTK with IC50 of 0.18 uM; irreversibly inhibits BTK, demonstrating superior kinome selectivity and is potent in B cell receptor, Fc receptor, and TLR-9-dependent cellular assays; inhibits antibody responses to thymus-independent and thymus-dependent antigens, paw swelling and bone destruction in rat collagen induced arthritis (CIA), and reduced disease in an IFNα-accelerated lupus nephritis model.

MSDS

TITLE	DOWNLOAD
MSDS_13371_DC31047

COA

LOT NO.	DOWNLOAD

Cat. No.	Product name	Field of application
DC48043	BIIB091	BIIB091 is a novel reversible, selective, potent BTK inhibitor with Kd of 0.07 nM.
DC47718	AS-1763	AS-1763 is an orally available, potent, and selective BTK inhibitor and shows excellent potency against both wild/C481S mutant BTKs with IC50 of 0.85 nM/0.99 nM.
DC47717	TAK-020	TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
DC42420	Tolebrutinib	Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant of Bruton tyrosine kinase (BTK), with IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib can be used for the research of multiple sclerosis (MS).
DC40447	N-piperidine Ibrutinib hydrochloride	N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent BTK inhibitor with IC50s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively. N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620. SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM.
DC39103	Remibrutinib (LOU064)	Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases.
DC28073	CNX-500	CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC50 of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn.
DC11471	BGB-3111(Zanubrutinib)	Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.
DC10044	ONO4059 analog	The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
DC5146	RN486	RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor.